88 results on '"Dickler MN"'
Search Results
2. Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)
- Author
-
Spoerke, JM, primary, Daemen, A, additional, Chang, C-W, additional, Giltnane, J, additional, Metcalfe, C, additional, Dickler, MN, additional, Bardia, A, additional, Perez Fidalgo, JA, additional, Mayer, IA, additional, Boni, V, additional, Winer, EP, additional, Hamilton, EP, additional, Bellet, M, additional, Urruticoechea, A, additional, Gonzalez Martin, A, additional, Cortes, J, additional, Martin, M, additional, Gates, M, additional, Cheeti, S, additional, Fredrickson, J, additional, Wang, X, additional, Friedman, LS, additional, Liu, L, additional, Li, R, additional, Chan, IT, additional, Mueller, L, additional, Milan, S, additional, Lauchle, J, additional, Humke, EW, additional, and Lackner, MR, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy
- Author
-
Polley, M-YC, primary, Dickler, MN, additional, Johnston, S, additional, Goetz, MP, additional, de la Haba, J, additional, Loibl, S, additional, Mehta, RS, additional, Bergh, J, additional, Roberston, J, additional, Barlow, W, additional, Liu, H, additional, Tenner, K, additional, and Martin, M, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
- Author
-
Rugo, HS, primary, Kabos, P, additional, Dickler, MN, additional, John, WJ, additional, Smith, I, additional, Lu, Y, additional, Young, S, additional, and Tolaney, SM, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
- Author
-
Dickler, MN, primary, Villanueva, R, additional, Perez Fidalgo, JA, additional, Mayer, IA, additional, Boni, V, additional, Winer, EP, additional, Hamilton, EP, additional, Bellet, M, additional, Urruticoechea, A, additional, Gonzalez-Martin, A, additional, Cortes, J, additional, Martin, M, additional, Giltnane, J, additional, Gates, M, additional, Cheeti, S, additional, Fredrickson, J, additional, Wang, X, additional, Friedman, LS, additional, Spoerke, JM, additional, Metcalfe, C, additional, Liu, L, additional, Li, R, additional, Morley, R, additional, McCurry, U, additional, Chan, IT, additional, Mueller, L, additional, Milan, S, additional, Lauchle, J, additional, Humke, EW, additional, and Bardia, A, additional
- Published
- 2018
- Full Text
- View/download PDF
6. Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
- Author
-
Dickler, MN, primary, Saura, C, additional, Oliveira, M, additional, Richards, DA, additional, Krop, IE, additional, Cervantes, A, additional, Stout, TJ, additional, Jin, H, additional, Savage, HM, additional, Wilson, TR, additional, and Baselga, J, additional
- Published
- 2017
- Full Text
- View/download PDF
7. Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
- Author
-
Iyengar, NM, primary, Smyth, L, additional, Lake, D, additional, Gucalp, A, additional, Singh, JC, additional, Traina, TA, additional, DeFusco, P, additional, Dickler, MN, additional, Fornier, MN, additional, Goldfarb, S, additional, Jhaveri, K, additional, Modi, S, additional, Troso-Sandoval, T, additional, Argolo, D, additional, Jack, K, additional, Ulaner, G, additional, Jochelson, M, additional, Baselga, J, additional, Norton, L, additional, Hudis, CA, additional, and Dang, CT, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
- Author
-
Goetz, MP, primary, Beeram, M, additional, Beck, T, additional, Conlin, AK, additional, Dees, EC, additional, Dickler, MN, additional, Helsten, TL, additional, Conkling, PR, additional, Edenfield, WJ, additional, Richards, DA, additional, Turner, PK, additional, Cai, N, additional, Chan, EM, additional, Pant, S, additional, Becerra, CH, additional, Kalinsky, K, additional, Puhalla, SL, additional, Rexer, BN, additional, Burris, HA, additional, and Tolaney, SM, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
- Author
-
Iyengar, NM, primary, Datko, FM, additional, D'Andrea, G, additional, Dickler, MN, additional, Goldfarb, S, additional, Theodoulou, M, additional, Lake, D, additional, Fornier, MN, additional, Modi, S, additional, Fasano, J, additional, Comen, E, additional, Gajria, D, additional, Moynahan, ME, additional, Traina, TA, additional, Patil, S, additional, Liu, J, additional, Jochelson, M, additional, Norton, L, additional, Hudis, CA, additional, and Dang, CT, additional
- Published
- 2013
- Full Text
- View/download PDF
10. Abstract P2-16-12: An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
- Author
-
Cadoo, KA, primary, Morris, PG, additional, Lake, DE, additional, D'Andrea, GM, additional, Dickler, MN, additional, Gilewski, TA, additional, Dang, CT, additional, McArthur, HL, additional, Bromberg, JF, additional, Goldfarb, SB, additional, Modi, S, additional, Robson, ME, additional, Seidman, AD, additional, Sklarin, NT, additional, Norton, L, additional, Hudis, CA, additional, and Fornier, MN, additional
- Published
- 2013
- Full Text
- View/download PDF
11. Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
- Author
-
Mayer, IA, primary, Bardia, A, additional, Dickler, MN, additional, Manning, HC, additional, Mahmood, U, additional, Ulaner, GA, additional, Hager, JH, additional, Rix, P, additional, Zack, N, additional, Maneval, EC, additional, Chen, I, additional, Baselga, J, additional, and Arteaga, CL, additional
- Published
- 2013
- Full Text
- View/download PDF
12. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
- Author
-
Mayer, EL, primary, Ligibel, JA, additional, Burstein, HJ, additional, Peppercorn, JM, additional, Miller, KD, additional, Carey, LA, additional, Dickler, MN, additional, Mayer, IA, additional, Forero, A, additional, Eng-Wong, J, additional, Pletcher, PJ, additional, Ryabin, N, additional, Gelman, R, additional, Wolff, AC, additional, and Winer, EP, additional
- Published
- 2011
- Full Text
- View/download PDF
13. Abstract P5-08-01: Oncology Clinicians’ Knowledge, Attitudes and Practices Regarding Fertility Preservation
- Author
-
Goldfarb, SB, primary, Dickler, MN, additional, McCabe, MS, additional, Thom, B, additional, Jia, X, additional, Margolies, A, additional, Norton, L, additional, Hudis, C, additional, Basch, E, additional, and Kelvin, JF., additional
- Published
- 2010
- Full Text
- View/download PDF
14. Abstract P2-14-08: Patient Perspectives on Information Communicated Regarding Effects of Treatment on Fertility
- Author
-
Goldfarb, SB, primary, Kelvin, JF, additional, Thom, B, additional, Kaplan, J, additional, Corcoran, S, additional, Margolies, A, additional, McCabe, MS, additional, Norton, L, additional, Hudis, C, additional, Basch, E, additional, and Dickler, MN., additional
- Published
- 2010
- Full Text
- View/download PDF
15. Bone scintigraphy (BS) may no longer be relevant in the era of integrated PET/CT for women undergoing evaluation for suspected metastatic breast cancer (MBC).
- Author
-
McArthur, HL, primary, Lynch, C, additional, Morris, P, additional, Larson, S, additional, Grabski, K, additional, Howard, J, additional, Patil, S, additional, Hudis, CA, additional, and Dickler, MN, additional
- Published
- 2009
- Full Text
- View/download PDF
16. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.
- Author
-
McArthur, HL, primary, Rugo, H, additional, Nulsen, B, additional, Traina, T, additional, Patil, S, additional, Zhou, Q, additional, Steingart, R, additional, Dang, C, additional, Park, J, additional, Moasser, M, additional, Melisko, M, additional, Sugarman, S, additional, Norton, L, additional, Hudis, C, additional, and Dickler, MN, additional
- Published
- 2009
- Full Text
- View/download PDF
17. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
- Author
-
Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA, Ellis, Matthew J, Gao, Feng, Dehdashti, Farrokh, Jeffe, Donna B, Marcom, P Kelly, Carey, Lisa A, and Dickler, Maura N
- Abstract
Context: Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy.Objective: To determine whether 6 mg of estradiol (daily) is a viable therapy for postmenopausal women with advanced aromatase inhibitor-resistant hormone receptor-positive breast cancer.Design, Setting, and Patients: A phase 2 randomized trial of 6 mg vs 30 mg of oral estradiol used daily (April 2004-February 2008 [enrollment closed]). Eligible patients (66 randomized) had metastatic breast cancer treated with an aromatase inhibitor with progression-free survival (> or = 24 wk) or relapse (after > or = 2 y) of adjuvant aromatase inhibitor use. Patients at high risk of estradiol-related adverse events were excluded. Patients were examined after 1 and 2 weeks for clinical and laboratory toxicities and flare reactions and thereafter every 4 weeks. Tumor radiological assessment occurred every 12 weeks. At least 1 measurable lesion or 4 measurable lesions (bone-only disease) were evaluated for tumor response.Intervention: Randomization to receive 1 oral 2-mg generic estradiol tablet 3 times daily or five 2-mg tablets 3 times daily.Main Outcome Measures: Primary end point: clinical benefit rate (response plus stable disease at 24 weeks).Secondary Outcomes: toxicity, progression-free survival, time to treatment failure, quality of life, and the predictive properties of the metabolic flare reaction detected by positron emission tomography/computed tomography with fluorodeoxyglucose F 18.Results: The adverse event rate (> or = grade 3) in the 30-mg group (11/32 [34%]; 95% confidence interval [CI], 23%-47%) was higher than in the 6-mg group (4/34 [18%]; 95% CI, 5%-22%; P = .03). Clinical benefit rates were 9 of 32 (28%; 95% CI, 18%-41%) in the 30-mg group and 10 of 34 (29%; 95% CI, 19%-42%) in the 6-mg group. An estradiol-stimulated increase in fluorodeoxyglucose F 18 uptake (> or = 12% prospectively defined) was predictive of response (positive predictive value, 80%; 95% CI, 61%-92%). Seven patients with estradiol-sensitive disease were re-treated with aromatase inhibitors at estradiol progression, among which 2 had partial response and 1 had stable disease, suggesting resensitization to estrogen deprivation.Conclusions: In women with advanced breast cancer and acquired resistance to aromatase inhibitors, a daily dose of 6 mg of estradiol provided a similar clinical benefit rate as 30 mg, with fewer serious adverse events. The efficacy of treatment with the lower dose should be further examined in phase 3 clinical trials.Trial Registration: clinicaltrials.gov Identifier: NCT00324259. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
18. Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: a bumpy start with an uncertain future.
- Author
-
Dickler MN
- Published
- 2011
19. The Henry/Giles/Stearn article reviewed. Aromatase inhibitors and arthralgia: a growing pain?
- Author
-
Murphy C, Hudis CA, and Dickler MN
- Published
- 2008
20. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
- Author
-
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, and Bardia A
- Subjects
- Humans, Female, Receptors, Estrogen genetics, Postmenopause, Estrogen Receptor Antagonists, Positron-Emission Tomography, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology
- Abstract
Purpose: GDC-0927 is a novel, potent, nonsteroidal, orally bioavailable, selective estrogen receptor (ER) degrader that induces tumor regression in ER+ breast cancer xenograft models., Patients and Methods: This phase I dose-escalation multicenter study enrolled postmenopausal women with ER+/HER2- metastatic breast cancer to determine the safety, pharmacokinetics, and recommended phase II dose of GDC-0927. Pharmacodynamics was assessed with [18F]-fluoroestradiol (FES) PET scans., Results: Forty-two patients received GDC-0927 once daily. The MTD was not reached. The most common adverse events (AE) regardless of causality were nausea, constipation, diarrhea, arthralgia, fatigue, hot flush, back pain, and vomiting. There were no deaths, grade 4/5 AEs, or treatment-related serious AEs. Two patients experienced grade 2 AEs of special interest of deep vein thrombosis and jugular vein thrombosis, both considered unrelated to GDC-0927. Following dosing, approximately 1.6-fold accumulation was observed, consistent with the observed half-life and dosing frequency. There were no complete or partial responses. Pharmacodynamics was supported by >90% reduction in FES uptake and an approximately 40% reduction in ER expression, suggesting ER degradation is not the mechanistic driver of ER antagonism. Twelve patients (29%) achieved clinical benefit; 17 patients (41%) showed a confirmed best overall response of stable disease. Baseline levels of ER and progesterone receptor protein and mutant ESR1 circulating tumor DNA did not correlate with clinical benefit., Conclusions: GDC-0927 appeared to be well tolerated with pharmacokinetics supporting once-daily dosing. There was evidence of target engagement and preliminary evidence of antitumor activity in heavily pretreated patients with advanced/metastatic ER+/HER2- breast cancer with and without ESR1 mutations., (©2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
21. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
- Author
-
Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, and Innocenti F
- Subjects
- Bevacizumab administration & dosage, Carboplatin administration & dosage, Cetuximab administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms genetics, Neoplasms pathology, Paclitaxel administration & dosage, Prognosis, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Genome-Wide Association Study, Neoplasms drug therapy
- Abstract
Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide association studies (GWAS) was conducted in 1,520 patients from Phase III trials (CALGB 80303, 40503, 80405 and ICON7), where bevacizumab was randomized to treatment without bevacizumab. We aimed to identify genes and single nucleotide polymorphisms (SNPs) associated with survival independently of bevacizumab treatment or through interaction with bevacizumab. A cause-specific Cox model was used to test the SNP-OS association in both arms combined (prognostic), and the effect of SNPs-bevacizumab interaction on OS (predictive) in each study. The SNP effects across studies were combined using inverse variance. Findings were tested for replication in advanced colorectal and ovarian cancer patients from The Cancer Genome Atlas (TGCA). In the GWAS meta-analysis, patients with rs680949 in PRUNE2 experienced shorter OS compared to patients without it (P = 1.02 × 10
-7 , hazard ratio [HR] = 1.57, 95% confidence interval [CI] 1.33-1.86), as well as in TCGA (P = .0219, HR = 1.58, 95% CI 1.07-2.35). In the GWAS meta-analysis, patients with rs16852804 in BARD1 experienced shorter OS compared to patients without it (P = 1.40 × 10-5 , HR = 1.51, 95% CI 1.25-1.82) as well as in TCGA (P = 1.39 × 10-4 , HR = 3.09, 95% CI 1.73-5.51). Patients with rs3795897 in AGAP1 experienced shorter OS in the bevacizumab arm compared to the nonbevacizumab arm (P = 1.43 × 10-5 ). The largest GWAS meta-analysis of bevacizumab treated patients identified PRUNE2 and BARD1 (tumor suppressor genes) as prognostic genes of colorectal and ovarian cancer, respectively, and AGAP1 as a potentially predictive gene that interacts with bevacizumab with respect to patient survival., (© 2021 UICC.)- Published
- 2022
- Full Text
- View/download PDF
22. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
- Author
-
Polley MC, Dickler MN, Sinnwell J, Tenner K, de la Haba J, Loibl S, Goetz MP, Bergh J, Roberston J, Couch F, Ellis MJ, and Martin M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Female, Fulvestrant therapeutic use, Humans, Receptor, ErbB-2, Receptors, Estrogen, Breast Neoplasms drug therapy
- Abstract
Purpose: Endocrine therapy (ET) is an effective strategy to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) but nearly all patients eventually progress. Our goal was to develop and validate a web-based clinical calculator for predicting disease outcomes in women with HR+ABC who are candidates for receiving first-line single-agent ET., Methods: The meta-database comprises 891 patient-level data from the control arms of five contemporary clinical trials where patients received first-line single-agent ET (either aromatase inhibitor or fulvestrant) for ABC. Risk models were constructed for predicting 24-months progression-free survival (PFS-24) and 24-months overall survival (OS-24). Final models were internally validated for calibration and discrimination using ten-fold cross-validation., Results: Higher number of sites of metastases, measurable disease, younger age, lower body mass index, negative PR status, and prior endocrine therapy were associated with worse PFS. Final PFS and OS models were well-calibrated and associated with cross-validated time-dependent area under the curve (AUC) of 0.61 and 0.62, respectively., Conclusions: The proposed ABC calculator is internally valid and can accurately predict disease outcomes. It may be used to predict patient prognosis, aid planning of first-line treatment strategies, and facilitate risk stratification for future clinical trials in patients with HR+ABC. Future validation of the proposed models in independent patient cohorts is warranted., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
23. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
- Author
-
Carter J, Baser RE, Goldfrank DJ, Seidel B, Milli L, Stabile C, Canty J, Saban S, Goldfarb S, Dickler MN, Gardner GJ, Jewell EL, Sonoda Y, Kollmeier MA, and Alektiar KM
- Subjects
- Adult, Aged, Atrophy, Breast Neoplasms pathology, Breast Neoplasms therapy, Endometrial Neoplasms pathology, Endometrial Neoplasms therapy, Female, Humans, Longitudinal Studies, Middle Aged, Postmenopause physiology, Prospective Studies, Vaginal Creams, Foams, and Jellies therapeutic use, Aromatase Inhibitors therapeutic use, Cancer Survivors, Hyaluronic Acid therapeutic use, Vagina pathology, Vaginal Diseases drug therapy, Vulva pathology
- Abstract
Purpose: To assess the feasibility and efficacy of a non-hormonal hyaluronic acid (HLA) vaginal gel in improving vulvovaginal estrogen-deprivation symptoms in postmenopausal women with a history of hormone receptor-positive (HR+) cancer., Methods: For this single-arm, prospective longitudinal trial, we identified disease-free patients with a history of HR+ breast cancer treated with aromatase inhibitors or HR+ endometrial cancer treated with surgery and postoperative radiation. Participants used HLA daily for the first 2 weeks, and then 3×/week until weeks 12-14; dosage was then increased to 5×/week for non-responders. Vulvovaginal symptoms and pH were assessed at 4 time points (baseline [T1], 4-6 weeks [T2], 12-14 weeks [T3], 22-24 weeks [T4]) with clinical evaluation, the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), Female Sexual Function Index (FSFI), and Menopausal Symptom Checklist (MSCL)., Results: Of 101 patients, mean age was 55 years (range, 31-78), 68% (n = 69) were partnered, and 60% (n = 61) were sexually active. In linear mixed models, VAS/VuAS scores significantly improved at all assessment points (all p < 0.001). MSCL scores similarly improved (all p < 0.001). FSFI scores significantly improved from T1 to T2 (p < 0.03), T3 (p < 0.001), and T4 (p < 0.001). Severe vaginal pH (> 6.5) decreased from 26% at T1 to 19% at T4 (p = 0.18)., Conclusions: HLA moisturization improved vulvovaginal health/sexual function of cancer survivors. While HLA administration 1-2×/week is recommended for women in natural menopause, a 3-5×/week schedule appears to be more effective for symptom relief in cancer survivors.
- Published
- 2021
- Full Text
- View/download PDF
24. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
- Author
-
Goldfarb SB, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler MN, and Oktay KH
- Subjects
- Anti-Mullerian Hormone, Chemotherapy, Adjuvant, Female, Humans, Tamoxifen adverse effects, Breast Neoplasms drug therapy, Ovarian Reserve
- Abstract
Purpose: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on the reproductive potential of women with breast cancer by using a sensitive ovarian reserve marker anti-Mullerian hormone (AMH) as a surrogate., Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate + 5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI., Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p < 0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p = 0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery., Conclusions: Both AC-based regimens and CMF significantly compromise ovarian reserve, without a recovery beyond 12 months post-chemotherapy. In contrast, tamoxifen-only treatment does not seem to alter ovarian reserve. These data indicate that the commonly used chemotherapy regimens but not the hormonal therapy compromise future reproductive potential.
- Published
- 2021
- Full Text
- View/download PDF
25. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
- Author
-
Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, and Tolaney SM
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Capecitabine therapeutic use, Female, Humans, Proportional Hazards Models, Receptor, ErbB-2, Vinorelbine therapeutic use, Breast Neoplasms drug therapy
- Abstract
Purpose: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared overall survival (OS) and duration of therapy (DoT) between MONARCH 1 and a real-world single-agent chemotherapy cohort., Methods: The real-world chemotherapy cohort was created from a Flatiron Health electronic health records-derived database based on key eligibility criteria from MONARCH 1. The chemotherapies included in the cohort were single-agent capecitabine, gemcitabine, eribulin, or vinorelbine. Results were adjusted for baseline demographics and clinical differences using Mahalanobis distance matching (primary analysis) and entropy balancing (sensitivity analysis). OS and DoT were analyzed using the Kaplan-Meier method and Cox proportional hazards regression., Results: A real-world single-agent chemotherapy cohort (n = 281) with eligibility criteria similar to the MONARCH 1 population (n = 132) was identified. The MONARCH 1 (n = 108) cohort was matched to the real-world chemotherapy cohort (n = 108). Median OS was 22.3 months in the abemaciclib arm versus 13.6 months in the matched real-world chemotherapy cohort with an estimated hazard ratio (HR) of 0.54. The median DoT was 4.1 months in MONARCH 1 compared to 2.9 months in the real-world chemotherapy cohort with HR of 0.76., Conclusions: This study demonstrates an approach to create a real-world chemotherapy cohort suitable to serve as a comparator for trial data. These exploratory results suggest a survival advantage and place the benefit of abemaciclib monotherapy in clinical context.
- Published
- 2020
- Full Text
- View/download PDF
26. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
- Author
-
Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, and Dickler MN
- Subjects
- Adult, Animals, Anti-Mullerian Hormone blood, Biomarkers blood, Breast Neoplasms genetics, Female, Humans, Longitudinal Studies, Mice, Oocytes pathology, Ovarian Reserve genetics, Primary Ovarian Insufficiency blood, Primary Ovarian Insufficiency genetics, Primary Ovarian Insufficiency physiopathology, Prospective Studies, Time Factors, Treatment Outcome, Antineoplastic Agents adverse effects, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms drug therapy, DNA Breaks, Double-Stranded, DNA Repair, Germ-Line Mutation, Oocytes drug effects, Ovarian Reserve drug effects, Primary Ovarian Insufficiency chemically induced
- Abstract
Objective: To assess whether woman who have BRCA mutations (WBM) experience more declines in ovarian reserve after chemotherapy treatment, as it induces oocyte death by deoxyribonucleic acid (DNA) damage, and BRCA mutations result in DNA damage repair deficiency., Design: Longitudinal cohort study., Setting: Academic centers., Patient(s): The 108 evaluable women with breast cancer were stratified into those never tested (negative family history; n = 35) and those negative (n = 59) or positive (n = 14) for a pathogenic BRCA mutation., Intervention(s): Sera were longitudinally obtained before and 12-24 months after chemotherapy treatment, assayed for antimüllerian hormone (AMH), and adjusted for age at sample collection., Main Outcome Measure(s): Ovarian recovery, defined as the geometric mean of the after chemotherapy age-adjusted AMH levels compared with baseline levels., Result(s): Compared with the controls, the before chemotherapy treatment AMH levels were 24% and 34% lower in those negative or positive for BRCA mutations, consistent with accelerated ovarian aging in WBM. The WBM had a threefold difference in AMH recovery after chemotherapy treatment (1.6%), when compared with BRCA negative (3.7%) and untested/low risk controls (5.2%). Limiting the analysis to the most common regimen, doxorubicin and cyclophosphamide followed by paclitaxel, showed similar results. These findings were mechanistically confirmed in an in vitro mouse oocyte BRCA knockdown bioassay, which showed that BRCA deficiency results in increased oocyte susceptibility to doxorubicin., Conclusion(s): Women who have pathogenic BRCA mutations are more likely to lose ovarian reserve after chemotherapy treatment, suggesting an emphasis on fertility preservation. Furthermore, our findings generate the hypothesis that DNA repair deficiency is a shared mechanism between aging, infertility, and cancer., Clinical Trial Registration Number: NCT00823654., (Copyright © 2020 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
- Author
-
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, and Chandarlapaty S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Estrogen Receptor Modulators therapeutic use, Female, Humans, PTEN Phosphohydrolase genetics, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Thiazoles, Aromatase Inhibitors pharmacology, Breast Neoplasms drug therapy
- Abstract
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma circulating tumor DNA among such patients from a phase I/II trial combining alpelisib with an aromatase inhibitor (AI) (NCT01870505). The trial's primary objective was to establish safety with maculopapular rash emerging as the most common grade 3 adverse event (33%). Among 44 evaluable patients, the observed clinical benefit rate was 52%. Correlating genetic alterations with outcome, we identified loss-of-function PTEN mutations in 25% of patients with resistance. ESR1 activating mutations also expanded in number and allele fraction during treatment and were associated with resistance. These data indicate that genomic alterations that mediate resistance to alpelisib or antiestrogen may promote disease progression and highlight PTEN loss as a recurrent mechanism of resistance to PI3Kα inhibition., Competing Interests: Competing Interests P.R. reports consulting or advisory role for Novartis, AstraZeneca, Foundation Medicine, and institutional research support from Illumina and GRAIL; M.N.D. is an employee of Eli Lilly, P.D.S. reports consulting with Tmnity and research funding from AstraZeneca; B.T.L. reports consulting/advisory board for Genentech, ThermoFisher Scientific, Guardant Health, Hengrui Therapeutics, Mersana Therapeutics, Biosceptre Australia and institutional research support from Illumina, GRAIL, Genentech, AstraZeneca; N.V. reports consulting or advisory role for Novartis; K.J. reports consulting or advisory role for ADC Therapeutics; AstraZeneca; Jounce therapeutics; Novartis; Pfizer; Spectrum; Taiho, research funding from ADC Therapeutics (Inst); Clovis Oncology (Inst); Debio (Inst); Genentech (Inst); Novartis (Inst); Novita (Inst); Pfizer (Inst) and other relationship with Jounce Therapeutics; Novartis; Pfizer; Taiho; A.C. reports being an advisory board member for Accurate Medical a Stockholder for Amgen; L.N. reports honoraria from Advanced Breast Cancer 4 International Consensus Conference; Bluprint Oncology Concepts; Celgene; Context Therapeutics; MCI Breast Cancer Symposium, consulting or advisory role for Advanced Breast Cancer International Consensus Conference; Bluprint Oncology Concepts; Celgene; Context Therapeutics; MCI Breast Cancer Symposium and travel, accommodations, expenses from Advanced Breast Cancer International Consensus Conference; Celgene; MCI Breast Cancer Symposium; A.S., R.J.N., J.I.O., and R.B.L. are employees and stockholders of Guardant Health; M.E.R. reports honoraria from AstraZeneca, consulting or advisory role for AstraZeneca; McKesson; Merck; Pfizer, research funding from Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst), and travel, accommodations, expenses from AstraZeneca; M.E.L. reports serving as a consultant or speaking for Legacy Healthcare Services, Adgero Bio, Amryt, Celldex, Debiopharm, Galderma, Johnson & Johnson, Novocure, Lindi, Merck, Sharp and Dohme Corp, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis, Roche, AbbVie, Boehringer Ingelheim, Allergan, Amgen, E. R. Squibb & Sons, LLC, EMD Serono, AstraZeneca, Genentech, Leo Pharma, Seattle Genetics, Bayer, Manner, SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality, Novartis, Our Brain Bank, and Takeda Millenium; and receiving research funding from Veloce, US Biotest, Berg, BMS, Lutris, Paxman, and Novocure; J.S.R-F reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche, Genentech and Invicro; D.B.S. received honoraria and consulted for Pfizer, Loxo, Vivideon, Illumina and Lilly Oncology; M.S. is in the Advisory Board of Bioscience Institute and Menarini Ricerche, received research funds from Puma Biotechnology, Daiichi Sankyo, Targimmune, Immunomedics and Menarini Ricerche, is a co-founder of Medendi Medical Travel and received honoraria from Menarini Ricerche and ADC; S.C. reports institutional research funding from Novartis, Eli Lilly, Sanofi, Daiichi Sankyo, Genentech and Ad hoc consulting for Novartis, Context Therapeutics, Sermonix, Eli Lilly, BMS, and Revolution Medicine. The other coauthors report no competing interests.
- Published
- 2020
- Full Text
- View/download PDF
28. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
- Author
-
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, and Baselga J
- Subjects
- Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases chemistry, Class Ia Phosphatidylinositol 3-Kinase chemistry, Class Ia Phosphatidylinositol 3-Kinase metabolism, Female, Humans, Mutation, Neoplasms drug therapy, Neoplasms pathology, Phosphoinositide-3 Kinase Inhibitors therapeutic use, Protein Binding, Protein Domains, Thiazoles pharmacology, Carcinogenesis genetics, Class I Phosphatidylinositol 3-Kinases genetics, Class I Phosphatidylinositol 3-Kinases metabolism, Drug Resistance, Neoplasm genetics, Neoplasms genetics, Phosphoinositide-3 Kinase Inhibitors pharmacology
- Abstract
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed PIK3CA -mutant cancer genomes and observed the presence of multiple PIK3CA mutations in 12 to 15% of breast cancers and other tumor types, most of which (95%) are double mutations. Double PIK3CA mutations are in cis on the same allele and result in increased PI3K activity, enhanced downstream signaling, increased cell proliferation, and tumor growth. The biochemical mechanisms of dual mutations include increased disruption of p110α binding to the inhibitory subunit p85α, which relieves its catalytic inhibition, and increased p110α membrane lipid binding. Double PIK3CA mutations predict increased sensitivity to PI3Kα inhibitors compared with single-hotspot mutations., (Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2019
- Full Text
- View/download PDF
29. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
- Author
-
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, and Dickler MN
- Subjects
- Adult, Aged, Aged, 80 and over, Bevacizumab administration & dosage, Bone Neoplasms metabolism, Bone Neoplasms secondary, Breast Neoplasms metabolism, Breast Neoplasms pathology, Evaluation Studies as Topic, Female, Follow-Up Studies, Fulvestrant administration & dosage, Humans, Letrozole administration & dosage, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Prognosis, Soft Tissue Neoplasms metabolism, Soft Tissue Neoplasms secondary, Survival Rate, Tamoxifen administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms drug therapy, Breast Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Soft Tissue Neoplasms drug therapy
- Abstract
Background: Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results., Patients and Methods: We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria., Results: The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33)., Conclusion: The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity., Trials Registration: ClinicalTrial.Gov NCT00545077 and NCT00601900., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
30. Correction: 18 F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.
- Author
-
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, and Ulaner GA
- Published
- 2019
- Full Text
- View/download PDF
31. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
- Author
-
Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, and Baselga J
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms genetics, Breast Neoplasms pathology, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions classification, Drug-Related Side Effects and Adverse Reactions pathology, Female, Fulvestrant administration & dosage, Fulvestrant adverse effects, Humans, Imidazoles adverse effects, Middle Aged, Mutation, Oxazepines adverse effects, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms drug therapy, Class I Phosphatidylinositol 3-Kinases genetics, Imidazoles administration & dosage, Oxazepines administration & dosage
- Abstract
Purpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer. Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity. Tumor tissue (if available) was centrally evaluated for PIK3CA mutations. Adverse events (AE) were recorded using NCI-CTCAE v4.0. Tumor response was investigator-determined using RECIST v1.1. Results: Median treatment duration was 4.6 (range: 0.9-40.5) months. All patients experienced ≥1 AE, 30 (50.0%) had grade ≥3 AEs, and 19 (31.7%) experienced 35 serious AEs. Forty-seven of 60 patients had evaluable tissue for central PIK3CA mutation testing [20 had mutations, 27 had no mutation detected (MND)]. In patients with baseline measurable disease, clinical activity was observed in tumors with PIK3CA mutations [best confirmed response rate: 38.5% (5/13; 95% CI, 13.9-68.4); clinical benefit rate (CBR): 38.5% (5/13; 95% CI, 13.9-68.4)], PIK3CA -MND [best confirmed response rate: 14.3% (3/21; 95% CI, 3.0-36.3); CBR: 23.8% (5/21; 95% CI, 8.2-47.2)], and unknown PIK3CA mutation status [best confirmed response rate: 20.0% (2/10; 95% CI, 2.5-55.6); CBR: 30.0% (3/10; 95% CI, 6.7-65.2)]. Conclusions: Taselisib plus fulvestrant had clinical activity irrespective of PIK3CA mutation status, with numerically higher objective response rate and CBR in patients with PIK3CA -mutated (vs. -MND) locally advanced or metastatic HER2-negative, HR-positive breast cancer. No new safety signals were reported. A confirmatory phase III trial is ongoing. Clin Cancer Res; 24(18); 4380-7. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
32. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
- Author
-
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, and Baselga J
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms, Male drug therapy, Breast Neoplasms, Male pathology, Estrogen Receptor alpha genetics, Estrogen Receptor alpha metabolism, Female, Gene Expression Regulation, Neoplastic, Genomics, Humans, Male, Middle Aged, Mutation, Neurofibromin 1 genetics, Neurofibromin 1 metabolism, Prospective Studies, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Receptors, Progesterone genetics, Receptors, Progesterone metabolism, Young Adult, Antineoplastic Agents, Hormonal pharmacology, Breast Neoplasms genetics, Breast Neoplasms, Male genetics, Drug Resistance, Neoplasm genetics, MAP Kinase Signaling System genetics
- Abstract
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 tumors previously exposed to hormonal therapy, we identified an increased number of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery. Activating ERBB2 mutations and NF1 loss-of-function mutations were more than twice as common in endocrine resistant tumors. Alterations in other MAPK pathway genes (EGFR, KRAS, among others) and estrogen receptor transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were also enriched. Altogether, these alterations were present in 22% of tumors, mutually exclusive with ESR1 mutations, and associated with a shorter duration of response to subsequent hormonal therapies., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
- Author
-
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, and Hurria A
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab administration & dosage, Breast Neoplasms pathology, Female, Humans, Incidence, Letrozole administration & dosage, Middle Aged, Odds Ratio, Risk Factors, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
- Abstract
Background: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk for toxicity while receiving letrozole plus bevacizumab for hormone receptor-positive advanced breast cancer., Methods: CALGB 40503 was a phase III trial that enrolled patients with hormone receptor-positive advanced breast cancer randomized to letrozole with or without bevacizumab. Patients randomized to bevacizumab were approached to complete a validated assessment tool evaluating physical function, comorbidity, cognition, psychological state, social support, and nutritional status. The relationship between pretreatment assessment measures and the incidence of grade ≥ 3 (National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0) adverse events was determined., Results: One hundred thirteen (58%) of 195 patients treated with letrozole plus bevacizumab completed the pretreatment assessment questionnaire. One patient was excluded due to missing adverse event data. The median age of patients was 56. Frequently reported grade ≥ 3 adverse events were hypertension (26%), pain (20%), and proteinuria (7%). Two hemorrhagic events (one grade 5) and 1 thrombosis event occurred. Age ≥ 65 years (p < 0.01), decreased vision (p = 0.04), and poorer pretreatment physical function measures (p < 0.05) were found on univariate analysis to be significantly associated with increased incidence of grade ≥ 3 adverse events. Upon multivariate analysis, age ≥ 65 years (p = 0.01) and decreased vision (p = 0.04) remained significant. Univariable and multivariable logistic regression models demonstrated associations between age, vision, the ability to walk up flights of stairs, and grade ≥ 3 adverse events., Conclusions: Age (≥ 65 years), decreased vision, and impairments in physical function correlated with increased incidence of toxicity in patients receiving first-line letrozole plus bevacizumab. When evaluating therapy likely to increase toxicity, functional assessment measures can identify patients at increased risk for side effects who may benefit from closer monitoring.
- Published
- 2018
- Full Text
- View/download PDF
34. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
- Author
-
Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, Dickler MN, Robson ME, and Mao JJ
- Subjects
- Acupuncture Therapy adverse effects, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Contusions etiology, Female, Humans, Middle Aged, Neoadjuvant Therapy, Paclitaxel administration & dosage, Paclitaxel adverse effects, Peripheral Nervous System Diseases chemically induced, Peripheral Nervous System Diseases pathology, Severity of Illness Index, Treatment Outcome, Acupuncture Therapy methods, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Peripheral Nervous System Diseases therapy
- Abstract
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side-effect of neurotoxic chemotherapy for cancer patients. We evaluated the preliminary efficacy of acupuncture in preventing worsening CIPN in patients receiving paclitaxel., Methods: In this phase IIA single-arm clinical trial, we screened stage I-III breast cancer patients receiving neoadjuvant/adjuvant weekly paclitaxel for development of CIPN. The primary objective was to assess acupuncture's efficacy in preventing the escalation of National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0, grade II CIPN to higher grades. Acupuncture was deemed worthy of further study if 23 or more of the 27 enrolled patients did not develop grade III CIPN. Outcome measures (NCI-CTCAE CIPN grade, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-Ntx], Neuropathic Pain Scale [NPS]) were obtained weekly during the intervention., Results: Of 104 patients screened, 37 developed grade II CIPN (36%), and 28 (27%) enrolled into the intervention phase; one was removed due to protocol violation. Of the 27 patients receiving acupuncture, 26 completed paclitaxel treatment without developing grade III CIPN, meeting our prespecified success criteria for declaring acupuncture worthy of further study. FACT/GOG-Ntx and NPS scores remained stable during the intervention while continuing weekly paclitaxel. Acupuncture treatment was well tolerated; 4 of 27 (15%) patients reported grade I bruising., Conclusions: Acupuncture was safe and showed preliminary evidence of effectiveness in reducing the incidence of high grade CIPN during chemotherapy. A follow-up randomised controlled trial is needed to establish definitive efficacy in CIPN prevention for patients at risk., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
35. Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
- Author
-
Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J 2nd, Sasso J, Yu A, Chandarlapaty S, Dang CT, Comen EA, Dickler MN, Peppercorn JM, and Jones LW
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Exercise Therapy adverse effects, Feasibility Studies, Female, Humans, Middle Aged, Oxygen Consumption physiology, Treatment Outcome, Young Adult, Breast Neoplasms rehabilitation, Exercise physiology, Exercise Therapy methods, Patient Reported Outcome Measures, Quality of Life
- Abstract
Background: The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety of aerobic training in metastatic breast cancer., Methods: Sixty-five women (age, 21-80 years) with metastatic (stage IV) breast cancer (57% were receiving chemotherapy, and >40% had ≥ 2 lines of prior therapy) were allocated to an aerobic training group (n = 33) or a stretching group (n = 32). Aerobic training consisted of 36 supervised treadmill walking sessions delivered thrice weekly between 55% and 80% of peak oxygen consumption (VO
2peak ) for 12 consecutive weeks. Stretching was matched to aerobic training with respect to location, frequency, duration, and intervention length. The primary endpoint was aerobic training feasibility, which was a priori defined as the lost to follow-up (LTF) rate (<20%) and attendance (≥70%). Secondary endpoints were safety, objective outcomes (VO2peak and functional capacity), and patient-reported outcomes (PROs; quality of life)., Results: One of the 33 patients (3%) receiving aerobic training was LTF, whereas the mean attendance rate was 63% ± 30%. The rates of permanent discontinuation and dose modification were 27% and 49%, respectively. Intention-to-treat analyses indicated improvements in PROs, which favored the attention control group (P values > .05). Per protocol analyses indicated that 14 of 33 patients (42%) receiving aerobic training had acceptable tolerability (relative dose intensity ≥ 70%), and this led to improvements in VO2peak and functional capacity (P values < .05)., Conclusions: Aerobic training at the dose and schedule tested is safe but not feasible for a significant proportion of patients with metastatic breast cancer. The acceptable feasibility and promising benefit for select patients warrant further evaluation in a dose-finding phase 1/2 study. Cancer 2018;124:2552-60. © 2018 American Cancer Society., (© 2018 American Cancer Society.)- Published
- 2018
- Full Text
- View/download PDF
36. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
- Author
-
Brufsky AM and Dickler MN
- Subjects
- Breast Neoplasms pathology, Female, Humans, Signal Transduction, Breast Neoplasms drug therapy, Receptors, Estrogen metabolism
- Abstract
Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded our understanding of breast cancer (BC) pathogenesis and hold promising implications for the future of therapy. The estrogen receptor-α is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. Successful targeting of proteins and genes within estrogen receptor (ER) nuclear and nonnuclear pathways remains a clinical goal. Several classes of antiestrogenic agents are available for patients with early, advanced, or metastatic BC, including selective ER modulators, aromatase inhibitors, and a selective ER degrader. Clinical development is focused upon characterizing the efficacy and tolerability of inhibitors that target the phosphatidylinositol 3 kinase (PI3K)/akt murine thymoma viral oncogene (AKT)/mammalian target of rapamycin inhibitor (mTOR) signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) cell cycle pathway in women with hormone receptor-positive, human epidermal growth receptor 2-negative BC who have demonstrated disease recurrence or progression. De novo and acquired resistance remain a major challenge for women with BC receiving antiestrogenic therapy. Therefore, sequential combination of targeted ET is preferred in these patients, and the ever-increasing understanding of resistance mechanisms may better inform the selection of future therapy. This review describes the intricate roles of the PI3K/AKT/mTOR and CDK4/6 pathways in intracellular signaling and the use of endocrine and endocrine-based combination therapy in BC., Implications for Practice: The foundational strategy for treating hormone receptor-positive, human epidermal growth receptor 2-negative, advanced breast cancer includes the use of endocrine therapy either alone or in combination with targeted agents. The use of combination therapy aims to downregulate cell-signaling pathways with the intent of minimizing cellular "crosstalk," which can otherwise result in continued tumorigenesis or progression through redundant pathways. This review provides the clinician with the molecular rationale and clinical evidence for these treatments and refers to evidence-based guidelines to inform the decision-making process., Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article., (© AlphaMed Press 2018.)
- Published
- 2018
- Full Text
- View/download PDF
37. Checkpoint Inhibitors in the Treatment of Breast Cancer.
- Author
-
Lyons TG, Dickler MN, and Comen EE
- Subjects
- Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen metabolism, Biomarkers, Tumor metabolism, Breast Neoplasms immunology, Breast Neoplasms metabolism, Breast Neoplasms pathology, CTLA-4 Antigen antagonists & inhibitors, CTLA-4 Antigen metabolism, Female, Humans, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor metabolism, Receptor, ErbB-2 metabolism, Antineoplastic Agents pharmacology, Breast Neoplasms drug therapy, Immunotherapy methods
- Abstract
Purpose of Review: The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer., Recent Findings: The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal. Clinical studies suggest response rates between 5 and 10% in pretreated patients and roughly 20-25% for untreated advanced TNBC. However, in the small subset of patients who do respond, the response is often durable. More encouraging results have been reported with their use in combination with chemotherapy in the neoadjuvant setting. Larger phase III studies are underway to confirm these earlier findings. An immune-directed therapeutic approach for the management of BC is underway, and it is likely that combination therapy will be required to achieve a level of efficacy worthy of use in the BC treatment paradigm. These agents are not without both economic and clinical toxicity; therefore, it is imperative that we identify patients most likely to benefit from these therapies through well-designed biologically plausible clinical studies and by evaluating novel combinatorial approaches with informative biomarker driven correlative studies.
- Published
- 2018
- Full Text
- View/download PDF
38. Genetic predisposition to bevacizumab-induced hypertension.
- Author
-
Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, and Levine DA
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological adverse effects, Case-Control Studies, Female, G-Protein-Coupled Receptor Kinase 4 genetics, Genetic Predisposition to Disease, Haplotypes, Humans, Kallikreins genetics, Male, Middle Aged, Neoplasms drug therapy, Polymorphism, Single Nucleotide, WNK Lysine-Deficient Protein Kinase 1 genetics, Bevacizumab adverse effects, Hypertension chemically induced, Hypertension genetics
- Abstract
Objective: Bevacizumab, a monoclonal antibody to VEGF, has shown efficacy in ovarian, cervical and endometrial cancer in addition to several other solid tumors. Serious side effects include hypertension, proteinuria, bowel perforation, and thrombosis. We tested the hypothesis that genetic variation in hypertension-associated genes is associated with bevacizumab-induced hypertension (BIH)., Methods: Patients with solid tumors treated with bevacizumab in combination with other therapy were identified from six clinical trials. Haplotype-tagging (ht) SNPs for 10 candidate genes associated with hypertension were identified through the International Hapmap Project. Germline DNA was genotyped for 103 htSNPs using mass spectrometry. Bevacizumab toxicities were identified from clinical trial reports. Haplotypes were reconstructed from diploid genotyping data and frequencies were compared using standard two-sided statistical tests., Results: The study included 114 patients with breast, lung, ovarian, or other cancers, of whom 38 developed BIH. WNK1, KLKB1, and GRK4 were found to contain single loci associated with BIH. Haplotype analysis of WNK1, KLKB1, and GRK4 identified risk haplotypes in each gene associated with grade 3/4 BIH. A composite risk model was created based on these haplotypes. Patients with the highest risk score were the most likely to develop grade 3/4 BIH (OR=6.45; P=0.005; 95%CI, 1.86-22.39)., Conclusions: We concluded that genetic variation in WNK1, KLKB1, and GRK4 may be associated with BIH. These genes are biologically plausible mediators due to their role in blood pressure control, regulating sodium homeostasis and vascular tone. This preliminary risk model performed better than population-based risk models and when further validated may help risk-stratify patients for BIH prior to initiating therapy., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
39. Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.
- Author
-
Schleicher SM and Dickler MN
- Abstract
Purpose of the Review: To understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor positive (HR+) breast cancer., Recent Findings: Multiple large trials have investigated this question. The two trials most representative of the dilemma faced in clinical practice are the MA.17R and NSABP-B42 trials, which both investigated the benefit of continuing versus stopping AI therapy beyond 5 years. Both trials showed that extended AI therapy led to a reduction in new or recurrent breast cancers, but had no effect on survival outcomes when death from any cause was included., Summary: The decision to extend AI therapy beyond 5 years remains a personalized one based on a discussion of the projected risk of recurrence, the expected benefits of prolonged AI treatment, and the patient's ability to tolerate side effects so that quality of life is preserved., Competing Interests: Conflict of Interest Maura N. Dickler has served as a consultant for Roche/Genentech, Novartis, Astra Zeneca, Puma, G1 Therapeutics, TapImmune, Pfizer, and Syndax. S.M. Schleicher declares no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
40. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
- Author
-
Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, and Offit K
- Subjects
- Aged, Biomarkers, Tumor genetics, DNA Mutational Analysis methods, Female, Genetic Predisposition to Disease, Genetic Testing, Humans, Male, Middle Aged, Phenotype, Prospective Studies, DNA, Neoplasm analysis, Germ-Line Mutation, Neoplasms genetics
- Abstract
Importance: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for cancer screening or prevention., Objective: To determine the proportion and potential clinical implications of inherited variants detected using simultaneous sequencing of the tumor and normal tissue ("tumor-normal sequencing") compared with genetic test results based on current guidelines., Design, Setting, and Participants: From January 2014 until May 2016 at Memorial Sloan Kettering Cancer Center, 10 336 patients consented to tumor DNA sequencing. Since May 2015, 1040 of these patients with advanced cancer were referred by their oncologists for germline analysis of 76 cancer predisposition genes. Patients with clinically actionable inherited mutations whose genetic test results would not have been predicted by published decision rules were identified. Follow-up for potential clinical implications of mutation detection was through May 2017., Exposure: Tumor and germline sequencing compared with the predicted yield of targeted germline sequencing based on clinical guidelines., Main Outcomes and Measures: Proportion of clinically actionable germline mutations detected by universal tumor-normal sequencing that would not have been detected by guideline-directed testing., Results: Of 1040 patients, the median age was 58 years (interquartile range, 50.5-66 years), 65.3% were male, and 81.3% had stage IV disease at the time of genomic analysis, with prostate, renal, pancreatic, breast, and colon cancer as the most common diagnoses. Of the 1040 patients, 182 (17.5%; 95% CI, 15.3%-19.9%) had clinically actionable mutations conferring cancer susceptibility, including 149 with moderate- to high-penetrance mutations; 101 patients tested (9.7%; 95% CI, 8.1%-11.7%) would not have had these mutations detected using clinical guidelines, including 65 with moderate- to high-penetrance mutations. Frequency of inherited mutations was related to case mix, stage, and founder mutations. Germline findings led to discussion or initiation of change to targeted therapy in 38 patients tested (3.7%) and predictive testing in the families of 13 individuals (1.3%), including 6 for whom genetic evaluation would not have been initiated by guideline-based testing., Conclusions and Relevance: In this referral population with selected advanced cancers, universal sequencing of a broad panel of cancer-related genes in paired germline and tumor DNA samples was associated with increased detection of individuals with potentially clinically significant heritable mutations over the predicted yield of targeted germline testing based on current clinical guidelines. Knowledge of these additional mutations can help guide therapeutic and preventive interventions, but whether all of these interventions would improve outcomes for patients with cancer or their family members requires further study., Trial Registration: clinicaltrials.gov Identifier: NCT01775072.
- Published
- 2017
- Full Text
- View/download PDF
41. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR + /HER2 - Metastatic Breast Cancer.
- Author
-
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, and Baselga J
- Subjects
- Adult, Aged, Aged, 80 and over, Aminopyridines adverse effects, Benzimidazoles adverse effects, Breast Neoplasms genetics, Breast Neoplasms pathology, Cyclin-Dependent Kinase 4 genetics, Cyclin-Dependent Kinase 6 genetics, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions classification, Drug-Related Side Effects and Adverse Reactions pathology, Female, Humans, Middle Aged, Neoplasm Metastasis, Prognosis, Receptor, ErbB-2 genetics, Treatment Outcome, Aminopyridines administration & dosage, Benzimidazoles administration & dosage, Breast Neoplasms drug therapy, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors
- Abstract
Purpose: The phase II MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor-positive (HR
+ ), HER2- metastatic breast cancer (MBC). Experimental Design: MONARCH 1 was a phase II single-arm open-label study. Women with HR+ /HER2- MBC who had progressed on or after prior endocrine therapy and had 1 or 2 chemotherapy regimens in the metastatic setting were eligible. Abemaciclib 200 mg was administered orally on a continuous schedule every 12 hours until disease progression or unacceptable toxicity. The primary objective of MONARCH 1 was investigator-assessed objective response rate (ORR). Other endpoints included clinical benefit rate, progression-free survival (PFS), and overall survival (OS). Results: Patients ( n = 132) had a median of 3 (range, 1-8) lines of prior systemic therapy in the metastatic setting, 90.2% had visceral disease, and 50.8% had ≥3 metastatic sites. At the 12-month final analysis, the primary objective of confirmed objective response rate was 19.7% (95% CI, 13.3-27.5; 15% not excluded); clinical benefit rate (CR+PR+SD≥6 months) was 42.4%, median progression-free survival was 6.0 months, and median overall survival was 17.7 months. The most common treatment-emergent AEs of any grade were diarrhea, fatigue, and nausea; discontinuations due to AEs were infrequent (7.6%). Conclusions: In this poor-prognosis, heavily pretreated population with refractory HR+ /HER2- metastatic breast cancer, continuous dosing of single-agent abemaciciclib was well tolerated and exhibited promising clinical activity. Clin Cancer Res; 23(17); 5218-24. ©2017 AACR ., (©2017 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
42. Sexual health needs and educational intervention preferences for women with cancer.
- Author
-
Stabile C, Goldfarb S, Baser RE, Goldfrank DJ, Abu-Rustum NR, Barakat RR, Dickler MN, and Carter J
- Subjects
- Adult, Aged, Cross-Sectional Studies, Female, Genital Neoplasms, Female diagnosis, Genital Neoplasms, Female epidemiology, Genital Neoplasms, Female psychology, Health Care Surveys, Health Services Needs and Demand, Humans, Middle Aged, Needs Assessment, Prevalence, Sexual Behavior, Sexual Dysfunction, Physiological diagnosis, Sexual Dysfunction, Physiological epidemiology, Sexual Dysfunction, Physiological psychology, Sexual Dysfunctions, Psychological diagnosis, Sexual Dysfunctions, Psychological epidemiology, Sexual Dysfunctions, Psychological psychology, Treatment Outcome, Vagina physiopathology, Young Adult, Genital Neoplasms, Female therapy, Health Knowledge, Attitudes, Practice, Patient Education as Topic methods, Patient Preference, Sexual Dysfunction, Physiological therapy, Sexual Dysfunctions, Psychological therapy, Sexual Health
- Abstract
Purpose: To assess sexual/vaginal health issues and educational intervention preferences in women with a history of breast or gynecologic cancer., Methods: Patients/survivors completed a cross-sectional survey at their outpatient visits. Main outcome measures were sexual dysfunction prevalence, type of sexual/vaginal issues, awareness of treatments, and preferred intervention modalities. Descriptive frequencies were performed, and results were dichotomized by age, treatment status, and disease site., Results: Of 218 eligible participants, 109 (50%) had a history of gynecologic and 109 (50%) a history of breast cancer. Median age was 49 years (range 21-75); 61% were married/cohabitating. Seventy percent (n = 153) were somewhat-to-very concerned about sexual function/vaginal health, 55% (n = 120) reported vaginal dryness, 39% (n = 84) vaginal pain, and 51% (n = 112) libido loss. Many had heard of vaginal lubricants, moisturizers, and pelvic floor exercises (97, 72, and 57%, respectively). Seventy-four percent (n = 161) had used lubricants, 28% moisturizers (n = 61), and 28% pelvic floor exercises (n = 60). Seventy percent (n = 152) preferred the topic to be raised by the medical team; 48% (n = 105) raised the topic themselves. Most preferred written educational material followed by expert discussion (66%, n = 144/218). Compared to women ≥50 years old (41%, n = 43/105), younger women (54%, n = 61/113) preferred to discuss their concerns face-to-face (p = 0.054). Older women were less interested in online interventions (52%, p < 0.001), despite 94% having computer access., Conclusion: Female cancer patients/survivors have unmet sexual/vaginal health needs. Preferences for receiving sexual health information vary by age. Improved physician-patient communication, awareness, and educational resources using proven sexual health promotion strategies can help women cope with treatment side effects.
- Published
- 2017
- Full Text
- View/download PDF
43. 18 F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.
- Author
-
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, and Ulaner GA
- Subjects
- Adult, Aged, Breast Neoplasms genetics, Breast Neoplasms pathology, Dose-Response Relationship, Drug, Estradiol administration & dosage, Estradiol analogs & derivatives, Estradiol chemistry, Female, Fulvestrant, Humans, Middle Aged, Molecular Imaging methods, Positron Emission Tomography Computed Tomography, Receptors, Estrogen antagonists & inhibitors, Receptors, Estrogen genetics, Tamoxifen administration & dosage, Biomarkers, Pharmacological, Breast Neoplasms drug therapy, Cinnamates administration & dosage, Estrogen Receptor alpha genetics, Indazoles administration & dosage, Molecular Targeted Therapy
- Abstract
Purpose: Evaluate
18 F-fluoroestradiol (FES) PET/CT as a biomarker of estrogen receptor (ER) occupancy and/or downregulation during phase I dose escalation of the novel ER targeting therapeutic GDC-0810 and help select drug dosage for subsequent clinical trials. Experimental Design: In a phase I clinical trial of GDC-0810, patients with ER-positive metastatic breast cancer underwent FES PET/CT before beginning therapy and at cycle 2, day 3 of GDC-0810 therapy. Up to five target lesions were selected per patient, and FES standardized uptake value (SUV) corrected for background was recorded for each lesion pretherapy and on-therapy. Complete ER downregulation was defined as ≥90% decrease in FES SUV. The effect of prior tamoxifen and fulvestrant therapy on FES SUV was assessed. Results: Of 30 patients who underwent paired FES-PET scans, 24 (80%) achieved ≥90% decrease in FES avidity, including 1 of 3 patients receiving 200 mg/day, 2 of 4 patients receiving 400 mg/day, 14 of 16 patients receiving 600 mg/day, and 7 of 7 patients receiving 800 mg/day. Withdrawal of tamoxifen 2 months prior to FES PET/CT and withdrawal of fulvestrant 6 months prior to FES PET/CT both appeared sufficient to prevent effects on FES SUV. A dosage of 600 mg GDC-0810 per day was selected for phase II in part due to decreases in FES SUV achieved in phase I. Conclusions: FES PET/CT was a useful biomarker of ER occupancy and/or downregulation in a phase I dose escalation trial of GDC-0810 and helped select the dosage of the ER antagonist/degrader for phase II trials. Clin Cancer Res; 23(12); 3053-60. ©2016 AACR ., (©2016 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
44. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
- Author
-
Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, and Baselga J
- Subjects
- Animals, Chromatin metabolism, Class I Phosphatidylinositol 3-Kinases genetics, DNA-Binding Proteins genetics, Female, HEK293 Cells, Hepatocyte Nuclear Factor 3-alpha genetics, Hepatocyte Nuclear Factor 3-alpha metabolism, Humans, Lysine genetics, Lysine metabolism, MCF-7 Cells, Metabolic Networks and Pathways, Methyltransferases genetics, Mice, Mice, Nude, Neoplasm Proteins genetics, Pre-B-Cell Leukemia Transcription Factor 1, Protein Processing, Post-Translational, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Receptors, Estrogen genetics, Breast Neoplasms genetics, Breast Neoplasms therapy, Class I Phosphatidylinositol 3-Kinases metabolism, DNA-Binding Proteins metabolism, Epigenesis, Genetic, Methyltransferases metabolism, Neoplasm Proteins metabolism, Receptors, Estrogen metabolism, Transcription, Genetic
- Abstract
Activating mutations in PIK3CA , the gene encoding phosphoinositide-(3)-kinase α (PI3Kα), are frequently found in estrogen receptor (ER)-positive breast cancer. PI3Kα inhibitors, now in late-stage clinical development, elicit a robust compensatory increase in ER-dependent transcription that limits therapeutic efficacy. We investigated the chromatin-based mechanisms leading to the activation of ER upon PI3Kα inhibition. We found that PI3Kα inhibition mediates an open chromatin state at the ER target loci in breast cancer models and clinical samples. KMT2D, a histone H3 lysine 4 methyltransferase, is required for FOXA1, PBX1, and ER recruitment and activation. AKT binds and phosphorylates KMT2D, attenuating methyltransferase activity and ER function, whereas PI3Kα inhibition enhances KMT2D activity. These findings uncover a mechanism that controls the activation of ER by the posttranslational modification of epigenetic regulators, providing a rationale for epigenetic therapy in ER-positive breast cancer., (Copyright © 2017, American Association for the Advancement of Science.)
- Published
- 2017
- Full Text
- View/download PDF
45. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
- Author
-
Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, and Brogi E
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant methods, Female, Follow-Up Studies, Gene Expression Profiling methods, Humans, Lymph Nodes pathology, Middle Aged, Neoplasm Metastasis drug therapy, Neoplasm Recurrence, Local drug therapy, Prognosis, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Receptors, Progesterone genetics, Tamoxifen therapeutic use, Young Adult, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms genetics, Breast Neoplasms pathology, Neoplasm Metastasis genetics, Neoplasm Metastasis pathology, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology
- Abstract
Background: A 21-gene expression assay (Oncotype DX recurrence score [RS]) that uses reverse transcriptase-polymerase chain reaction is used clinically in patients with early-stage, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast carcinoma (ER+/HER2- BC) to determine both prognosis with tamoxifen therapy and the usefulness of adding adjuvant chemotherapy. Use of the assay is associated with reductions in overall chemotherapy use. The current study examined the treatments and outcomes in patients with low RS., Methods: The authors reviewed the institutional database to identify patients with lymph node-negative, ER+/HER2- BC who were treated at the study institution between September 2008 and August 2013 and their 21-gene RS results., Results: A total of 1406 consecutive patients with lymph node-negative ER+/HER2- BC and a low RS were identified (510 patients had an RS of 0-10 and 896 patients had an RS of 11-17). The median age at the time of diagnosis of BC was 56 years; 63 patients (4%) were aged <40 years. Overall, 1361 patients (97%) received endocrine therapy and 170 patients (12%) received chemotherapy. The median follow-up was 46 months. Six patients (0.4%) developed distant metastases (1 patient with an RS of 5 and 5 patients with an RS of 11-17). In the cohorts of patients with an RS of 11 to 17, the absolute rate of distant metastasis among patients aged <40 years was 7.1% (3 of 42 patients) versus 0.2% among patients aged ≥40 years (2 of 854 patients)., Conclusions: The data from the current study document a 0.4% rate of distant metastasis within 5 years of BC diagnosis among patients with lymph node-negative ER+/HER2- BC with an RS <18. Patients aged <40 years at the time of BC diagnosis were observed to have a higher rate of distant metastases. Analysis of data from other studies is necessary to validate this observation further. Cancer 2017;131-137. © 2016 American Cancer Society., Competing Interests: The authors declare no conflict of interest., (© 2016 American Cancer Society.)
- Published
- 2017
- Full Text
- View/download PDF
46. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
- Author
-
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, and Burstein HJ
- Subjects
- Female, Humans, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
- Abstract
Purpose: To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC)., Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC., Recommendations: Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2-positive MBC, human epidermal growth factor receptor 2-targeted therapy plus an AI can be effective for those who are not chemotherapy candidates., (© 2016 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
47. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
- Author
-
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, and Hudis CA
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Female, Humans, Letrozole, Middle Aged, Nitriles administration & dosage, Treatment Outcome, Triazoles administration & dosage, Angiogenesis Inhibitors administration & dosage, Antineoplastic Agents administration & dosage, Bevacizumab administration & dosage, Breast Neoplasms drug therapy, Nitriles therapeutic use, Postmenopause, Triazoles therapeutic use
- Abstract
Purpose: To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor-positive metastatic breast cancer (MBC)., Patients and Methods: Women with hormone receptor-positive MBC were randomly assigned 1:1 in a multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) with or without bevacizumab (15 mg/kg intravenously once every 3 weeks) within strata defined by measurable disease and disease-free interval. This trial had 90% power to detect a 50% improvement in median PFS from 6 to 9 months. Using a one-sided α = .025, a target sample size of 352 patients was planned., Results: From May 2008 to November 2011, 350 women were recruited; 343 received treatment and were observed for efficacy and safety. Median age was 58 years (range, 25 to 87 years). Sixty-two percent had measurable disease, and 45% had de novo MBC. At a median follow-up of 39 months, the addition of bevacizumab resulted in a significant reduction in the hazard of progression (hazard ratio, 0.75; 95% CI, 0.59 to 0.96; P = .016) and a prolongation in median PFS from 15.6 months with letrozole to 20.2 months with letrozole plus bevacizumab. There was no significant difference in overall survival (hazard ratio, 0.87; 95% CI, 0.65 to 1.18; P = .188), with median overall survival of 43.9 months with letrozole versus 47.2 months with letrozole plus bevacizumab. The largest increases in incidence of grade 3 to 4 treatment-related toxicities with the addition of bevacizumab were hypertension (24% v 2%) and proteinuria (11% v 0%)., Conclusion: The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting., Competing Interests: Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. contributions are found at the end of this article., (© 2016 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
48. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.
- Author
-
Murphy CG and Dickler MN
- Subjects
- Autophagy, Breast Neoplasms genetics, Breast Neoplasms metabolism, Cell Cycle, Estrogen Receptor alpha genetics, Female, Humans, Mutation, Phosphatidylinositol 3-Kinases metabolism, Protein Kinases metabolism, Receptors, Growth Factor metabolism, Signal Transduction, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm genetics
- Abstract
The majority of breast cancers may be considered hormone responsive due to expression of hormone receptors (HR+). Although endocrine therapy is always considered for advanced HR+ breast cancer, the emergence of resistance is inevitable over time and is present from the start in a proportion of patients. In this review, we explore the mechanisms underlying de novo and acquired resistance to endocrine therapy. We comprehensively review newly approved and emerging therapies that have been developed to counteract specific mechanisms of resistance. We discuss the challenges pertinent to this therapeutic arena including the potential relief of negative regulatory feedback inhibition with compensatory pathway activation and the evolution of molecular changes in HR+ breast cancers during treatment. We discuss strategies to address these challenges in order to develop rational therapy approaches for patients with advanced HR+ breast cancer., (© 2016 Society for Endocrinology.)
- Published
- 2016
- Full Text
- View/download PDF
49. Cancer and Fertility Program Improves Patient Satisfaction With Information Received.
- Author
-
Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, Matasar MJ, Noy A, and Goldfarb SB
- Subjects
- Adolescent, Adult, Cross-Sectional Studies, Female, Fertility Preservation, Humans, Male, Middle Aged, Patient Education as Topic, Patient Satisfaction, Retrospective Studies, Fertility, Neoplasms physiopathology
- Abstract
Purpose: A cancer and fertility program was established at a large cancer center to support clinicians in discussing treatment-related fertility risks and fertility preservation (FP) options with patients and in referring patients to reproductive specialists. The program provides resources, clinician education, and fertility clinical nurse specialist consultation. This study evaluated the program's impact on patient satisfaction with information received., Patients and Methods: Retrospective cross-sectional surveys assessed satisfaction before (cohort 1 [C1]) and after (cohort 2 [C2]) program initiation. Questionnaires were investigator-designed, gender-specific, and anonymous., Results: Most C1 (150 males, 271 females) and C2 (120 males, 320 females) respondents were 2 years postdiagnosis; the most frequently reported cancers were testicular, breast, and lymphoma. A significant difference in satisfaction with the amount of information received was seen between C1 and C2. For males, satisfaction with information on fertility risks was high in both cohorts but significantly greater in C2 for information on sperm banking (χ(2) = 9.3, P = .01) and finding a sperm bank (χ(2) = 13.3, P = .001). For females, satisfaction with information was significantly greater in C2 for information on fertility risks (χ(2) = 62.1, P < .001), FP options (χ(2) = 71.9, P < .001), help with decision making (χ(2) = 80.2, P < .001), and finding a reproductive endocrinologist (χ(2) = 60.5, P < .001). Among patients who received and read information materials, 96% of males and 99% of females found them helpful. Among C2 females, fertility clinical nurse specialist consultation was associated with significantly greater satisfaction with information on FP options (χ(2) = 11.2, P = .004), help with decision making (χ(2) = 10.4, P = .006), and finding a reproductive endocrinologist (χ(2) = 22.6, P < .001), with 10% reporting lack of knowledge as a reason for not pursuing FP., Conclusion: Improvements in patient satisfaction with information received demonstrate the potential for fertility programs in cancer care settings to improve the quality of clinician-patient discussions about fertility., (© 2016 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
50. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
- Author
-
Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, and Robson ME
- Subjects
- Adult, Aged, Breast Neoplasms mortality, Breast Neoplasms pathology, Breast Neoplasms therapy, Cohort Studies, Databases, Factual, Disease-Free Survival, Female, Gene Expression Profiling, Humans, Logistic Models, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local epidemiology, Prognosis, Retrospective Studies, Risk Assessment, Survival Rate, United States, Young Adult, Breast Neoplasms genetics, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease epidemiology, Germ-Line Mutation, Neoplasm Recurrence, Local genetics
- Abstract
Background: Biological differences between BRCA-associated breast cancer and sporadic breast cancer may warrant different adjuvant chemotherapy (ACRx) recommendations despite similar phenotypic features. A 21-gene expression profile (Oncotype DX) generates a prognostic recurrence score (RS) that predicts the ACRx benefit in patients with hormone receptor-positive breast cancer. No reports describe assay results for BRCA-associated breast cancer., Methods: A review of Memorial Sloan Kettering Cancer Center databases identified 4908 patients with hormone receptor-positive, node-negative breast cancer who underwent Oncotype DX testing between July 2006 and March 2014. BRCA1/BRCA2 carriers (cases) were identified and matched (1:2) by age at diagnosis and tumor size to noncarrier controls. Two-sample nonparametric tests were used to compare the baseline characteristics, RSs, and risk stratification between BRCA1 and BRCA2 patients. Conditional logistic regression was used to assess these differences by mutational status., Results: Fifty mutation-associated cases (19 BRCA1 cases and 31 BRCA2 cases) and 100 controls who were well matched for age (P = .9) and tumor size (P = .6) were included. BRCA1 and BRCA2 carriers had similar median RSs (P = .6) and risk category stratification (P = .3). The median RS was higher for cases versus controls (24 vs 16; P < .0001). Risk stratification also differed by mutational status (P = .0002). Cases had more high-risk disease (28% vs 7%) and intermediate-risk disease (56% vs 36%) and less low-risk disease (16% vs 57%). Cases were more likely than controls to receive ACRx (74% vs 46%; P = .002)., Conclusions: Germline BRCA-associated hormone receptor-positive breast cancer may be associated with intrinsically less favorable biology. Few affected carriers have RS indicating a clear absence of benefit from ACRx. The increased use of ACRx and benefit from ACRx in BRCA carriers may mitigate otherwise inferior outcomes., (© 2016 American Cancer Society.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.